FI885331A - Inhibitering av arteriell, trombotisk ocklusion eller tromboemboli. - Google Patents

Inhibitering av arteriell, trombotisk ocklusion eller tromboemboli. Download PDF

Info

Publication number
FI885331A
FI885331A FI885331A FI885331A FI885331A FI 885331 A FI885331 A FI 885331A FI 885331 A FI885331 A FI 885331A FI 885331 A FI885331 A FI 885331A FI 885331 A FI885331 A FI 885331A
Authority
FI
Finland
Prior art keywords
trombotisk
tromboemboli
ocklusion
inhibitering
arteriell
Prior art date
Application number
FI885331A
Other languages
English (en)
Other versions
FI104790B (fi
FI885331A0 (fi
Inventor
John H Griffin
Andras Gruber
Stephen R Hanson
Lawrence A Harker
Original Assignee
Scripps Clinic Res
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=22398288&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=FI885331(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Scripps Clinic Res filed Critical Scripps Clinic Res
Publication of FI885331A0 publication Critical patent/FI885331A0/fi
Publication of FI885331A publication Critical patent/FI885331A/fi
Application granted granted Critical
Publication of FI104790B publication Critical patent/FI104790B/fi

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6424—Serine endopeptidases (3.4.21)
    • C12N9/6464—Protein C (3.4.21.69)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/164—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • A61K38/166—Streptokinase
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/49—Urokinase; Tissue plasminogen activator
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/21—Serine endopeptidases (3.4.21)
    • C12Y304/21069—Protein C activated (3.4.21.69)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Biomedical Technology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Compounds Of Unknown Constitution (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
  • External Artificial Organs (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
FI885331A 1987-11-17 1988-11-17 Menetelmä aktivoidun proteiini C:n valmistamiseksi FI104790B (fi)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US12170287 1987-11-17
US07/121,702 US5084274A (en) 1987-11-17 1987-11-17 Inhibition of arterial thrombotic occlusion or thromboembolism

Publications (3)

Publication Number Publication Date
FI885331A0 FI885331A0 (fi) 1988-11-17
FI885331A true FI885331A (fi) 1989-05-18
FI104790B FI104790B (fi) 2000-04-14

Family

ID=22398288

Family Applications (1)

Application Number Title Priority Date Filing Date
FI885331A FI104790B (fi) 1987-11-17 1988-11-17 Menetelmä aktivoidun proteiini C:n valmistamiseksi

Country Status (11)

Country Link
US (2) US5084274A (fi)
EP (1) EP0318201B1 (fi)
JP (1) JP2766986B2 (fi)
AT (1) ATE135234T1 (fi)
CA (1) CA1330036C (fi)
DE (1) DE3855096T2 (fi)
DK (1) DK175704B1 (fi)
ES (1) ES2086301T3 (fi)
FI (1) FI104790B (fi)
GR (1) GR3020036T3 (fi)
NO (1) NO301747B1 (fi)

Families Citing this family (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5084274A (en) * 1987-11-17 1992-01-28 Scripps Clinic And Research Foundation Inhibition of arterial thrombotic occlusion or thromboembolism
GB8819607D0 (en) * 1988-08-17 1988-09-21 Wellcome Found Novel combination
US5358932A (en) * 1989-12-29 1994-10-25 Zymogenetics, Inc. Hybrid protein C
CA2071630C (en) * 1989-12-29 2000-02-22 Donald C. Foster Hybrid protein c
US5571786A (en) * 1990-08-16 1996-11-05 Immuno Aktiengesellschaft Use of protein C or the activation peptide of protein C for preparing a pharmaceutical preparation
FR2671973A1 (fr) * 1991-01-25 1992-07-31 Fondation Nale Transfusion San Utilisation de la proteine c activee comme agent anti-agregant plaquettaire.
DE59204945D1 (de) * 1991-04-16 1996-02-15 Boehringer Mannheim Gmbh Pharmazeutische verpackungseinheit enthaltend plasminogenaktivatoren zur mehrfachbolusgabe
AT397615B (de) * 1991-05-14 1994-05-25 Immuno Ag Arzneimittel enthaltend protein c
AT402263B (de) * 1991-06-20 1997-03-25 Immuno Ag Pharmazeutische präparation enthaltend eine thrombolytisch wirkende substanz
AT395596B (de) * 1991-06-20 1993-01-25 Immuno Ag Verfahren zur herstellung von aktiviertem protein c
AT402262B (de) * 1991-06-20 1997-03-25 Immuno Ag Arzneimittel enthaltend aktiviertes protein c
WO1993009807A1 (en) * 1991-11-18 1993-05-27 The Scripps Research Institute Methods of inhibiting thrombosis via elevation of circulating endogenous activated protein c levels
JPH05271098A (ja) * 1992-03-26 1993-10-19 Teijin Ltd 活性化プロテインｃを有効成分とする抗血小板剤
DE4320294A1 (de) * 1993-06-18 1994-12-22 Immuno Ag Verwendung von humanem Protein C zur Verhinderung und Behandlung von Thrombozytenablagerungen
US5520912A (en) * 1993-07-02 1996-05-28 Immuno Aktiengesellschaft Prevention and treatment of ischemic events and reperfusion injury resulting therefrom using lys-plasminogen
JP3043558B2 (ja) * 1993-10-29 2000-05-22 財団法人化学及血清療法研究所 ヒト活性化プロテインｃ調製物及びその製法
US5510330A (en) * 1994-03-25 1996-04-23 Boehringer Mannheim Gmbh Combinations of thrombolytically active proteins and non-heparin anticoagulants, and uses thereof.
EP0871464B1 (en) * 1995-06-09 2003-04-02 The Regents Of The University Of Michigan Bradykinin analogs as selective thrombin inhibitors
BR9808063A (pt) * 1997-03-24 2000-06-06 Lilly Co Eli Métodos para tratamento de distúrbios vasculares.
US6982249B1 (en) 1997-04-23 2006-01-03 The Regents Of The University Of Michigan Bradykinin analogs as selective inhibitors of cell activation
PL337223A1 (en) * 1997-06-05 2000-08-14 Lilly Co Eli Method of treating thrombotic disorders
HUP0001237A3 (en) * 1997-10-20 2002-01-28 Lilly Co Eli Methods for treating vascular disorders
US6953568B1 (en) 1998-08-25 2005-10-11 Oklahoma Medical Research Foundation Targeting of molecules to large vessel endothelium using EPCR
ATE232739T1 (de) 1998-11-23 2003-03-15 Lilly Co Eli Protein c zur behandlung von sichelzellanämie und thalassämie
DE60144366D1 (de) 2000-02-04 2011-05-19 Scripps Research Inst Neuroprotektive, antithrombotische und anti-entzündliche anwendungen von aktiviertem protein c
US7204981B2 (en) 2000-03-28 2007-04-17 Eli Lilly And Company Methods of treating diseases with activated protein C
AU2001262939A1 (en) 2000-05-24 2001-12-03 Eli Lilly And Company Formulations and use of activated protein c and protein c zymogen for treating hypercoagulable states
US7759506B2 (en) 2002-02-25 2010-07-20 Diffusion Pharmaceuticals Llc Bipolar trans carotenoid salts and their uses
WO2004022153A2 (en) * 2002-09-05 2004-03-18 Genentech, Inc. Infusion catheter having an integrated doppler transducer
WO2004056309A2 (en) 2002-12-05 2004-07-08 Socratech L.L.C. Neuroprotective activity of activated protein c is independent of its anticoagulant activity
US20070142272A1 (en) * 2003-01-24 2007-06-21 Zlokovic Berislav V Neuroprotective activity of activated protein c independent of its anticoagulant activity
US9192657B2 (en) 2003-07-08 2015-11-24 The Scripps Research Institute Activated protein C variants with normal cytoprotective activity but reduced anticoagulant activity
EP1651252B1 (en) * 2003-07-08 2014-11-26 The Scripps Research Institute Activated protein c variants with normal cytoprotective activity but reduced anticoagulant activity
CA2574598A1 (en) * 2004-07-23 2006-02-09 The University Of Rochester Activated protein c inhibits undesirable effects of plasminogen activator in the brain
NZ561664A (en) 2005-02-24 2011-02-25 Diffusion Pharmaceuticals Llc Trans carotenoids, their synthesis, formulation and uses
US7785857B2 (en) * 2006-08-31 2010-08-31 Saint Louis University Protein C variant
CA2668187A1 (en) * 2006-10-31 2008-06-19 The Scripps Research Institute Dosing regimen of activated protein c and variants having reduced anticoagulant activity
EP2146948A4 (en) 2007-04-13 2010-08-04 Diffusion Pharmaceuticals Llc USE OF BIPOLAR TRANS-CAROTINOIDES AS PRE-TREATMENT AND TREATMENT OF PERIPHERAL VASCULAR DISEASE
JP5787884B2 (ja) * 2009-06-22 2015-09-30 ディフュージョン・ファーマシューティカルズ・エルエルシー 拡散増強化合物、及びその単独使用又は血栓溶解剤との併用
KR101891357B1 (ko) 2010-06-02 2018-08-24 디퓨젼 파마슈티컬즈 엘엘씨 양극성 트랜스 카로티노이드의 경구용 제형
CN104394883B (zh) 2012-07-04 2017-05-31 悉尼大学 炎性皮肤病症的治疗
PT3137102T (pt) 2014-04-16 2021-09-28 Zz Biotech Llc Apc para utilização no tratamento de cicatrização cutânea anormal
CN109152839A (zh) 2016-03-24 2019-01-04 扩散药品有限公司 双极性反式类胡萝卜素连同化疗和放射治疗在治疗癌症中的用途

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4766075A (en) * 1982-07-14 1988-08-23 Genentech, Inc. Human tissue plasminogen activator
JPS6011427A (ja) * 1983-06-29 1985-01-21 Green Cross Corp:The 血栓溶解性蛋白の疾患局所親和性向上方法
GB8319538D0 (en) * 1983-07-20 1983-08-24 Beecham Group Plc Compounds
DE3584902D1 (de) * 1984-02-29 1992-01-30 Asahi Chemical Ind Waessrige loesung eines darin in erhoehter konzentration aufgeloesten gewebe-plasminogen-aktivators und herstellungsverfahren.
AU595173B2 (en) * 1985-01-08 1990-03-29 General Hospital Corporation, The Method and use for site-specific activation of substances
US4775624A (en) * 1985-02-08 1988-10-04 Eli Lilly And Company Vectors and compounds for expression of human protein C
DE3688900T3 (de) * 1985-06-27 1998-06-10 Zymogenetics Inc Expression von Protein C.
US5084274A (en) * 1987-11-17 1992-01-28 Scripps Clinic And Research Foundation Inhibition of arterial thrombotic occlusion or thromboembolism
US4929602A (en) * 1987-11-25 1990-05-29 Scripps Clinic And Research Foundation Method of inhibiting platelet dependent arterial thrombosis

Also Published As

Publication number Publication date
DK640088A (da) 1989-05-18
US5350578A (en) 1994-09-27
DE3855096D1 (de) 1996-04-18
EP0318201A3 (en) 1990-02-07
FI104790B (fi) 2000-04-14
ATE135234T1 (de) 1996-03-15
EP0318201A2 (en) 1989-05-31
DE3855096T2 (de) 1996-07-25
ES2086301T3 (es) 1996-07-01
EP0318201B1 (en) 1996-03-13
NO885109D0 (no) 1988-11-16
DK640088D0 (da) 1988-11-16
NO301747B1 (no) 1997-12-08
FI885331A0 (fi) 1988-11-17
GR3020036T3 (en) 1996-08-31
JP2766986B2 (ja) 1998-06-18
NO885109L (no) 1989-05-18
JPH01238536A (ja) 1989-09-22
CA1330036C (en) 1994-06-07
DK175704B1 (da) 2005-01-24
US5084274A (en) 1992-01-28

Similar Documents

Publication Publication Date Title
FI885331A (fi) Inhibitering av arteriell, trombotisk ocklusion eller tromboemboli.
ES2043607T3 (es) Agentes fibrinoliticos modificados.
DK0519903T3 (da) Lægemiddel indeholdende aktiveret protein C
DE3751179T2 (de) Peptide, die die Bindung des Von-Willebrand-Faktors inhibieren.
DE3880480D1 (de) Hemolyse-inhibitor und plastifizierungsmittel.
DE69110713T2 (de) 7-Oxabicycloheptan-imidazol-prostaglandin-Analoge, verwendbar bei der Behandlung von thrombotischen und vasospastischen Erkrankungen.
ATE109465T1 (de) 4-aryl-4-piperidine (oder -pyrrolidin- oder - hexahydroazepin-) carbinole und heterocyclische analoga davon.
NZ230327A (en) Synergistic combination of t-pa and activated protein c (apc)
NO883963D0 (no) Modifiserte plasminogen-aktivatorer.
DE69023459D1 (de) Behandlung von pulmonarer Disfunktion mit 15-Keto-prostaglandin-Derivaten.
FI892051A (fi) Foerfarande foer framstaellning av 5-klor-3-klorsulfonyl-2-tiofencarbonsyraestrar.
DK213589D0 (da) Antistoffer mod fibrin og immunogen til brug ved fremstilling deraf
EP0214281A4 (en) PROTEIN-ABSORBING AGENTS.
NO871198D0 (no) Anvendelse av substituerte n-(triklormetyltiohydantoiner i kombinasjon med bis-(2,4-diamino-s-triazin-6-yl)-oligosulfider i vulkaniserbare kautsjukblandinger og slike kautsjukblandinger.
DK0458537T3 (da) Anvendelse af en terapeutisk forbindelse til behandling af bronkitis
DK301589A (da) Laegemiddel med thrombolytisk virkning
IT8423800A0 (it) Procedimento di trattamento di stati ipotrofici nel bambino mediante somministrazioni di aspartato di arginina.
CA2027593A1 (fr) Composition a activite anti-agregante plaquettaire utilisable en therapeutique
ES1005075Y (es) Mesa de billar articulada.
IL76121A0 (en) Protein absorption enhancing agents
ES1008159Y (es) Mesa de billar perfeccionada.

Legal Events

Date Code Title Description
FG Patent granted

Owner name: SCRIPPS CLINIC AND RESEARCH FOUNDATION

MA Patent expired